No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

MATCHPOINT trial

byKathleen Lau

June 12, 2022

in StudyGraphics

Reading Time: 1 min read

RELATED REPORTS

Inavolisib lengthens progression-free survival time in HER2-negative advanced breast cancer

RAMOSE Phase II trial finds promising results for osimertinib and ramucirumab in non-small cell lung cancer

Cadonilimab plus chemotherapy improves survival in recurrent or metastatic cervical cancer

#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication

RelatedReports

USPSTF recommends chemoprevention for women at high risk for breast cancer

Oncology

Inavolisib lengthens progression-free survival time in HER2-negative advanced breast cancer

December 11, 2024

Lessons from real-world implementation of lung cancer screening

Oncology

RAMOSE Phase II trial finds promising results for osimertinib and ramucirumab in non-small cell lung cancer

December 10, 2024

Cervical cancer screening practices less cost-effective than suggested guidelines

Chronic Disease

Cadonilimab plus chemotherapy improves survival in recurrent or metastatic cervical cancer

December 5, 2024

StudyGraphics

#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk

December 5, 2024

Long-term outcomes for off-pump and on-pump CABG are similar

2 Minute Medicine Rewind June 13, 2022

Multiple variables related to physical activity levels in preschool children

Blended physical literacy interventions may improve physical literacy in children

Neoadjuvant dostarlimab is a promising treatment option in locally advanced dMMR rectal cancer

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result